ORAMED PHARMACEUTICALS INC. - FORM 10-K - EX-32.2 - CERTIFICATION - November 25, 2016

Attached files

file filename
EX-10.32 - AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT, DATED JULY 24, 2016, BETWEEN HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES CO., LTD., ORAMED PHARMACEUTICALS, INC. AND ORAMED LTD. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxii_oramed.htm
EX-10.6 - AMENDMENT, DATED JUNE 27, 2016, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF NADAV KIDRON. - ORAMED PHARMACEUTICALS INC.f10k2016ex10vi_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2016ex23i_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex31i_oramed.htm
EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex32i_oramed.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex31ii_oramed.htm
EX-10.34 - GENERAL TECHNICAL AGREEMENT BETWEEN ORAMED LTD. AND PREMAS BIOTECH PVT. LTD., DATED JULY 24, 2016 - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxiv_oramed.htm
EX-10.33 - SERVICE AGREEMENT, DATED AS OF JUNE 3, 2016, BETWEEN ORAMED LTD. AND XERTECS GMBH - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxiii_oramed.htm
EX-10.31 - AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT, DATED JUNE 3, 2016, BETWEEN HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES CO., LTD., ORAMED PHARMACEUTICALS, INC. AND ORAMED LTD. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxi_oramed.htm
EX-10.25 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JUNE 27, 2016, BETWEEN ORAMED LTD. AND JOSHUA HEXTER. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxv_oramed.htm
EX-10.22 - LETTER AGREEMENT, DATED AS OF FEBRUARY 5, 2013, BETWEEN ORAMED PHARMACEUTICALS INC. AND REGALS CAPITAL LP. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxii_oramed.htm
EX-10.7 - AMENDMENT, DATED JUNE 27, 2016, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF MIRIAM KIDRON. - ORAMED PHARMACEUTICALS INC.f10k2016ex10vii_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2016_oramedpharma.htm

Exhibit 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

        In connection with the annual report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-K for the period ended August 31, 2016, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Yifat Zommer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

 

 1.   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and
   
 2.   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 24, 2016 By: /s/ Yifat Zommer
    Yifat Zommer
    Chief Financial Officer

Stock widget

Investing forum

ORAMED PHARMACEUTICALS INC. Reports